Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 15/20 | 0.51 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885841 | 1.00 | CXCR4 (0.51) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL9885845 | 1.00 | CXCR4 (0.51) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL13683489 | 0.94 | HTT (0.53) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL9884664 | 0.91 | CXCR4 (0.53) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL9884722 | 0.89 | CXCR4 (0.51) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL9884669 | 0.89 | CXCR4 (0.51) | CXCR4CXCL12 | |
| SCHEMBL9884654 | 0.89 | CXCR4 (0.51) | CXCR4CXCL12 | |
| SCHEMBL9885767 | 0.89 | CXCR4 (0.51) | CXCR4CXCL12 | |
| SCHEMBL9884667 | 0.88 | MEN1 (0.53) | CXCR4CXCL12HTTMEN1ALDH1A1 | |
| SCHEMBL9884729 | 0.88 | MEN1 (0.53) | CXCR4CXCL12HTTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | CXCR4 247/4885CXCL12 109/4885HTT 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.